Systemic Sclerosis
Conditions
Keywords
Breath-holding test, Six minute walk test, Systemic sclerosis
Brief summary
This study aims to evaluate the utility of breath-holding test as a marker of pulmonary disease severity in patients with systemic sclerosis.
Detailed description
Systemic sclerosis (SSc) is a chronic autoimmune disease of unknown etiology with high morbidity and mortality. SSc manifests by fibrosis of skin and internal organs. Although the underlying mechanisms are still subject to investigation, endothelial dysfunction and abnormal immune response are thought to contribute to vascular dysfunction and fibrosis in SSc. Pulmonary involvement, such as pulmonary arterial hypertension (PAH) and interstitial lung disease (ILD) is a major cause of death in SSc. Although the 6MWT is generally used for evaluating PAH and ILD, the utility in SSc is undetermined. Several investigators have found weak or moderate correlations of 6MWT in pulmonary involvement in SSc. The 6MWT is influenced by the status of all organ systems involved in exercise (pulmonary, cardiac, peripheral vascular, neuromuscular unit and muscle metabolism) as well as by specifics of test conditions. There is a pressing need for new, practical method which corroborates the current 6MWT for the evaluation of pulmonary disease severity in SSc. Breath-holding test (BHT) is one of the most useful methods for assessing the sensitivity of peripheral chemoreflex. Recent studies have demonstrated that BHT was correlated to pulmonary function test. BHT can be safely conducted and doctors handle a medical emergency during test easily as well. Therefore, this study evaluates the utility of BHT as surrogate marker of pulmonary involvement in patients with SSc.
Interventions
OTHERscleroderma health assessment questionnaire (SHAQ), BHT, and 6MWT
1. Participants will perform the SHAQ. 2. BHT and 6MWT will be performed in the randomized way for each participant. 3. For BHT, the participants will be told to sit comfortably on a chair, and breath normally. After 1 minute, they were required to make a maximum expiration followed by a maximum inspiration and to hold the breath as long as possible at maximum inspiratory level. This procedure was repeated three times, with 5-minute intervals between the tests. 4. 6MWT will be performed according to the ATS guidelines. 5. Information on CXR, TTE, and PFT (FVC%, DLCO%) will be obtained from the medical record if the data was obtained within 3 months. If not, the tests will be performed. 6. BHT and PFT will be followed by six months after the first breath-holding test to confirm the responsiveness. 7. Additional 30 patients with systemic sclerosis will be collected to perform the test-retest reliability of BHT.
Sponsors
Seoul National University Hospital
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
OTHER
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
19 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* A diagnosis of systemic sclerosis according to 2013 ACR/EULAR criteria * Must understand and voluntarily sign an informed consent form including writing consent for data protection
Exclusion criteria
* The resting oxygen saturation by pulse oximetry \< 90% in room air * Unstable angina or myocardial infarction during the previous month * Patients considered unable to the breath-holding test or 6 minute walk test
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Correlation of breath-holding test with Borg Dyspnea Index | Day 1 at inclusion | Borg Scale on a 0-10 point |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Correlation of breath-holding time with 6 minute walk test (6MWT) distance | Day 1 at inclusion | 6MWT distance measured in meters according to American Thoracic Society guidelines |
| Correlation of breath-holding time with oxygen saturation during 6MWT | Day 1 at inclusion | Oxygen saturation monitored by wearable pulse oximeter (Radius PPG™ Tetherless Pulse Oximetry, Masimo Corp., Irvine, CA, USA) |
| Correlation of breath-holding time with pulmonary function indices | Day 1 at inclusion | Pulmonary function indices including FVC (%) and DLCO (%) |
| Correlation of breath-holding time with data on the echocardiography | Day 1 at inclusion | Echocardiography including left ventricular ejection fraction and pulmonary arterial systolic pressure (mmHg) |
| Correlation of breath-holding time with scleroderma health assessment questionnaire (SHAQ) | Day 1 at inclusion | SHAQ ranging from 0 to 3 |
Other
| Measure | Time frame | Description |
|---|---|---|
| Changes of oxygen saturation during of 6MWT | Day 1 at inclusion | Oxygen saturation monitored by wearable pulse oximeter (Radius PPG™ Tetherless Pulse Oximetry, Masimo Corp., Irvine, CA, USA) |
| Responsiveness of breath-holding test | Month 6 at inclusion | Correlation of Δbreath-holding test and ΔPulmonary function indices after 6months |
| Reliability of breath-holding test | Day 1, and Day 7~Day14 at inclusion | Additional 30 patients collection for test-retest reliability |
| Development of the machine learning model to predict pulmonary parameters | Year 2 at inclusion | Developing two cohorts: Cohort 1 for training a ML model and internal validation; and Cohort 2 for external validation |
| Changes of oxygen saturation during breath-holding test | Day 1 at inclusion | Oxygen saturation monitored by radius or forehead pulse oximeter (Masimo Corp., Irvine, CA, USA) |
Countries
South Korea
Outcome results
None listed